The Technical Analyst
Nautilus Biotechnology, [NAUT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Nautilus Biotechnology, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.67% $2.36
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 295.23 mill |
| EPS: | -0.510 |
| P/E: | -4.63 |
| Earnings Date: | Apr 30, 2024 |
| SharesOutstanding: | 125.10 mill |
| Avg Daily Volume: | 0.0776 mill |
| RATING 2024-04-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.63 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.79x |
| Company: PE -4.63 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.122 (-105.17%) $-2.48 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.17 - 2.56 ( +/- 8.26%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-11 | Patel Sujal M | Buy | 12 044 | Common Stock |
| 2024-03-08 | Patel Sujal M | Buy | 2 430 | Common Stock |
| 2024-03-07 | Patel Sujal M | Buy | 18 854 | Common Stock |
| 2024-03-06 | Patel Sujal M | Buy | 9 267 | Common Stock |
| 2024-03-05 | Patel Sujal M | Buy | 7 405 | Common Stock |
| INSIDER POWER |
|---|
| 95.58 |
| Last 97 transactions |
| Buy: 21 218 105 | Sell: 5 493 083 |
Forecast:
16:00 - $2.34
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.34
Forecast 2: 16:00 - $2.34
Forecast 3: 16:00 - $2.34
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.36 (-1.67% ) |
| Volume | 0.0742 mill |
| Avg. Vol. | 0.0776 mill |
| % of Avg. Vol | 95.53 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NAUT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NAUT
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Last 10 Buy Signals
Latest Press Releases
2024-04-11 08:00:00 - Press Release
Nautilus Biotechnology To Announce First Quarter 2024 Financial Results On April 30, 2024
Seattle, april 11, 2024 (globe newswire) -- nautilus biotechnology, inc. (nasdaq: naut; or “nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on tuesday, april 30, 2024.
2024-02-28 08:00:00 - Press Release
Nautilus Biotechnology Reports Fourth Quarter And Fiscal Year 2023 Financial Results
Seattle, feb. 28, 2024 (globe newswire) -- nautilus biotechnology, inc. (nasdaq: naut; or “nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended december 31, 2023.
2024-02-22 08:00:00 - Press Release
Nautilus Biotechnology To Participate In The Td Cowen 44ᵗʰ Annual Healthcare Conference
Seattle, feb. 22, 2024 (globe newswire) -- nautilus biotechnology, inc. (nasdaq: naut; or “nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the td cowen 44th annual healthcare conference.
2024-02-07 08:00:00 - Press Release
Nautilus Biotechnology To Announce Fourth Quarter And Full Year 2023 Financial Results On February 28, 2024
Seattle, feb. 07, 2024 (globe newswire) -- nautilus biotechnology, inc. (nasdaq: naut; or “nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on wednesday, february 28, 2024.
2023-11-30 08:00:00 - Press Release
Nautilus Biotechnology Co-founder And Chief Scientist Parag Mallick, Ph.d., Honored With Us Hupo Computational Proteomics Award
Society award recognizes dr. mallick's decades of innovative leadership and science advancing the field of computational proteomics society award recognizes dr. mallick's decades of innovative leadership and science advancing the field of computational proteomics
Latest News
2024-02-28 13:13:04 - Seeking Alpha
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
2024-02-07 08:00:00 - GlobeNewsWire
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024.
2023-10-31 11:22:10 - Seeking Alpha
Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Carrie Mendivil - IR Sujal Patel - Co-Founder & CEO Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - CFO Conference Call Participants Yuko Oku - Morgan Stanley Daniel Brennan - Cowen Ivy Kozlowski - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
2023-10-11 08:05:00 - GlobeNewsWire
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023.
2023-08-04 08:00:00 - GlobeNewsWire
Nautilus Biotechnology to Participate in Upcoming August Investor Conferences
SEATTLE, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:
2023-08-02 13:33:02 - Seeking Alpha
Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Carrie Mendivil - Investor Relations Sujal Patel - Co-Founder, Chief Executive Officer, President, Secretary & Director Parag Mallick - Co-Founder, Chief Scientist & Director Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Dave Delahunt - Goldman Sachs Dan Brennan - Cowen Operator Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.
2023-07-11 09:23:00 - GlobeNewsWire
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter before market open on Wednesday, August 2, 2023.
2023-05-24 08:05:00 - GlobeNewsWire
Nautilus Biotechnology to Participate in Upcoming June Investor Conferences
SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:
2023-04-18 16:05:00 - GlobeNewsWire
Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023
SEATTLE, April 18, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter before market open on Tuesday, May 2, 2023.
2023-03-23 08:00:00 - GlobeNewsWire
Nautilus Biotechnology to Participate in B. Riley Securities' Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming B. Riley Securities' Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference.